Pharmacological treatment of neuropathic pain: Present status and future directions

Therapy

Volumn 3, Issue 5, 2006, Pages 651-677

  Bonicalzi, Vincenzo ^a   Canavero, Sergio ^a  

^a Turin Advanced Neuromodulation Group   (Italy)

Author keywords

Central pain; Mononeuropathy; Neuropathic pain; Polyneuropathy

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ADENOSINE; ADENOSINE A1 RECEPTOR ANTAGONIST; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CARBAMAZEPINE; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; GABAPENTIN; GLUTAMATE RECEPTOR ANTAGONIST; LAMOTRIGINE; LIDOCAINE; METHADONE; MEXILETINE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NORADRENALIN UPTAKE INHIBITOR; OXYCODONE; PHENYTOIN; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG DEPENDENCE; DRUG MECHANISM; DRUG RESEARCH; HUMAN; META ANALYSIS; MOTOR DYSFUNCTION; NEUROPATHIC PAIN; NONHUMAN; OPIATE ADDICTION; OUTCOMES RESEARCH; POSTHERPETIC NEURALGIA; REVIEW; SYSTEMATIC REVIEW;

EID: 33750088122     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.1586/14750708.3.5.651     Document Type: Review

References (125)

1. Canavero S, Bonicalzi V. Central Pain Syndrome. Cambridge University Press, UK (2006) (In Press).
2. Murphy D, Reid DB. Pain treatment satisfaction in spinal cord injury. Spinal Cord 39, 44-46 (2001).
3. Gilron I, Bailey J, Weaver DF et al. Patients' attitudes and prior treatments in neuropathic pain. A pilot study. Pain Res. Manag. 7, 199-203 (2002).
4. Finnerup NB, Johannesen IL, Sindrup SH, Bach FW, Jensen TS. Pharmacological treatment of spinal cord injury pain. Progr. Pain Res. Manag. 23, 341-351 (2002).
5. Canavero S, Bonicalzi V. The neurochemistry of central pain. evidence from clinical studies, hypothesis and therapeutic implications. Pain 74, 109-114 (1998).
6. Finnerup NB, Gottrup H, Jensen TS. Anticonvulsants in central pain. Expert Opin. Pharmacother. 3, 1411-1420 (2002).
7. Attal N. Chronic neuropathic pain: mechanisms and treatment. Clin. J. Pain 16, S118-S130 (2000).
8. Woolf CJ, Marinion RJ. Neuropathic pain: aetiology, symptoms, mechanisms and management. Lancet 353, 1959-1964 (1999).
9. Canavero S, Bonicalzi V, Dotta M et al. Low-rate ripetitive TMS allays central pain. Neurol. Res. 25, 151-152 (2003).
10. Canavero S, Bonicalzi V. Norepinephrine and pain Pain 107, 279 (2004).
11. Bonicalzi V, Canavero S, Cerutti A et al. The ordeal of chronic pain. Eur. Neurol. 40, 61-62 (1998).
12. Kauppila T. Correlation between autonomy-behavior and current theories of neuropathic pain. Neurosci. Biobehav. Rev. 23, 111-129 (1998).
13. Jensen TJ, Gottrup H, Kasch H et al. Has basic research contributed to chronic pain treatment? Acta Anesthesiol. Scand. 45, 1128-1135 (2001).
14. Canavero S, Bonicalzi V. Intrathecal ziconotide for chronic pain. JAMA 292(14), 1681-1682 (2004).
15. Millan M. Descending control of pain. Progr. Neurobiol. 66, 355-474 (2002).
16. Canavero S, Bonicalzi V. Neuromodulation for central pain. Expert Rev. Neurother. 3, 591-607 (2003).
17. Lin CR, Wu PC, Stith HC et al. Intrathecal spinal progenitor cell transplantation for the treatment of neuropathic pain. Cell Transplant 11, 17-24 (2002).
18. Pohl M, Meunier A, Hamon M et al. Gene therapy of chronic pain. Curr. Gene Ther. 3, 223-238 (2003).
19. LoGrasso P, McKelvy J. Advances in pain therapeutics. Curr. Opin. Chem. Biol. 7, 452-456 (2003).
20. Lersch C, Schmelz R, Eckel F et al. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanaced colorectal cancer. Clin. Colorectal Cancer 2, 54-58 (2002).
21. Lampi C, Yazdi K, Roper C. Amitriptyline in the prophylaxis of central poststroke pain: Preliminary results of 39 patients in a placebo-controlled, long-term study. Stroke 33, 3030-3032 (2002).
22. Bonicalzi V, Canavero S, Cerutti F et al. Lamotrigine reduces total postoperative analgesic requirement: a randomized, double-blind, placebo-controlled pilot study. Surgery 122, 567-570 (1997).
23. Bonicalzi V, Canavero S. CPRS: are guidelines possibile? Clin. J. Pain 15, 159-160 (1999),
24. Canavero S, Bonicalzi V. Intravenous subhypnotic propofol in central pain: a double-blind placebo-controlled crossover study. Clin. Neuropharmacol. 27, 182-186 (2004).
25. Ahmad M, Goucke C. Management strategies for the treatment of neuropathic pain in the elderly. Drugs Aging 19, 929-945 (2002).
26. Bonicalzi V, Canavero S. Sympathetic pain again? Lancet 360, 1426-1427 (2002).
27. Ochoa JL. Truths, errors, and lies around "reflex sympathetic dystrophy" and "complex regional pain syndrome". J. Neurol. 246, 875-879 (1999).
28. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opiod therapy for chronic peripheral and central neuropathic pain. N. Engl. J. Med. 348, 1223-1222 (2003).
29. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA 293, 3043-3052 (2005).
30. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N. Engl. J Med. 349, 1943-1953 (2003).
31. Morley JS, Bridson I, Nash TP et al. Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomised controlled crossover trial. Palliat. Med. 17, 576-587 (2003).
32. Canavero S, Bonicalzi V. Chronic neuropathic pain. N. Logl. J. Med. 348(26), 2688 (2003).
33. Iversen L, Chapman V. Cannabinoids: a real prospect for pain relief? Curr. Op. Pharmacol. 2, 50-55 (2002).
34. Chapman V, Finn DP. Analgesic effects of cannabinoids: sites and mechanisms of action. Analgesia 7, 25-39 (2003).
35. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids; an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 323, 13-16 (2001).
36. Berman J. Lee J, Cooper M et al. Efficacy of two cannabis-based medicinal extracts (100 microgram sprays) for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled study. Anaesthesia 58, 938 (2003).
37. Apfel S. Neurotrophic factors and pain. Clin. J. Pain 16, S7-S11 (2000).
38. Jaitly V, di Vadi PP. Efficacy of intravenous magnesium in neuropathic pain. Br. J. Anaesth. 91, 302 (2003).
39. Gilron I, Booher SC, Rowan JS et al. A randomised, controlled trial of high-dose dextrometorphan in facial neuralgia. Neurology 55, 964-971 (2000).
40. Coward K, Plumpton C, Facer P et al. Immunolocalization of SNS/PN3 and NaV/SNS2 sodium channels in human pain states. Pain 85, 41-50 (2000).
41. Bucknill AT, Coward K, Plumpton C et al. Nerve fibers in lumbar spine structures and injured spinal roots express the sensory neuron-specific sodium channels SNS/PN3 and NaN/SNS2. Spine 27, 135-140 (2002).
42. Wallace MS. Calcium and sodium channel antagonists for the treatment of pain. Clin. J. Pain 16, S80-S85 (2000).
43. Lai J, Hunter JC, Porreca F. The role of voltage-gated sodium channels in neuropathic pain. Curr. Opin. Neurobiol. 13, 291-297 (2003).
44. Kvarnstrom A, Karlsten R, Quiding H et al. The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain. Acta Anaesthesiol. Scand. 47, 868-877 (2003).
45. Williams M, Kowaluk EA, Arneric SP. Emerging molecular approaches to pain therapy. J. Med. Chem. 42, 1481-1500 (1999).
46. Hassenbusch SJ, Gunes S, Wachsman S et al. Intrathecal clonidine in the treatment of intractable pain: a phase I/II study. Pain Medicine 3, 85-91 (2002).
47. Ackerman LL, Follett KA, Rosenquist RW. Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations. J. Pain Symptom Manag. 26, 668-677 (2003).
48. Hood DD, Mallak KA, Eisenach JC et al. Interaction between intrathecal neostigmine and epidural clonidine in human volunteers. Anesthesiology 85, 315-325 (1996).
49. Eisenach JC, Rauck RL, Curry R. Intrathecal, but not intravenous adenosine, reduces allodynia in patients with neuropathic pain. Pain 105, 65-70 (2003).
50. Ji RR, Kohno T, Moore KA et al. Central sensitisation and LTP: do pain and memory share similar mechanisms? TINS 26, 696-705 (2003).
51. Canavero S, Bonicalzi V. Reversibile central pain. Neurol. Sci. 22, 271-273 (2001).
52. Finnerup NB, Otto M, Mc Quay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118, 289-305 (2005).
53. Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropathic pain. Basic Clin. Pharmacol. Toxicol. 96(6), 399-409 (2005).
54. Tremont-Lukats IW, Challapalli V, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetics to relieve neuropathic pain: asystematic review and meta-analysis. Anesth. Analg. 101(6), 1738-1749 (2005).
55. Wiffen PJ, McQuay HJ, Edwards JE, Moore RA. Gabapentin for acute and chronic pain. Cochrane Database Syst. Rev. (3), D005452 (2005).
56. Wiffen PJ, McQuay HJ, Moore RA. Carbamazepine for acute and chronic pain. Cochrane Database Syst. Rev. (3), CD005451 (2005).
57. Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst. Rev. (3), CD001133 (2005).
58. Adriaensen H, Plaghki L, Mathieu C, Joffroy A, Vissers K. Critical review of oral drug treatments for diabetic neuropathic pain-clinical outcomes based on efficacy and safety data from placebo-controlled and direct comparative studies. Diabetes Metab. Res. Rev. 21(3), 231-240 (2005).
59. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst. Rev. (3), CD005454 (2005).
60. Duhmke RM, Comblath DD, Hollingshead JRF. Tramadol for neuropathic pain. Cochrane Database Syst. Rev. (2), CD003726 (2004).
61. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C Ali H. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 63, 959-965 (2004).
62. Namaka M, Gramlich CR, Ruhlen D, Melanson M, Sutton I, Major J. A treatment algorithm for neuropathic pain. Clin. Ther. 26(7), 951-979 (2004).
63. Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 328, 991 (2004).
64. Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. Anesth. Analg. 97, 1730-1739 (2003).
65. Jensen TS. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur. J. Pain 6 (Suppl. A), 61-68 (2002).
66. McQuay HJ. Neuropathic pain: evidence matters. Eur. J. Pain 6 (Suppl. A), 11-18 (2002).
67. Mellegors MA, Furian AD, Mailis A. Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature. Clin. J. Pain 17(4), 284-295 (2001).
68. Lynch ME. Antidepressants as analgesics: a review of randomized controlled trials. J. Psyrbiatry Neurosci. 26(1), 30-36 (2001).
69. Collins SL, Moore RA, McQuay HJ, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J. Tain Symptom Manage. 20, 449-458 (2000).
70. Sindrup SH, Jensen TS. Pharmacologic treatment of pain in polyneuropathy. Neurology 55, 915-920 (2000).
71. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain 68 (2-3), 217-227 (1996).
72. Volmink J, Lancaster T, Gray S, Silagy C. Treatments for postherpetic neuralgia - a systematic review of randomized controlled trials. Fam. Pract. 13(1), 84-91 (1996).
73. Backonja MM. Anticonvulsants (antineuropathics) for neuropathic pain syndromes. Clin. J. Pain 16(2 Suppl.), S67-S72 (2000).
74. Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. Drugs 60, 1029-1052 (2000).
75. Sang CN. NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trias. J. Pain Symptom Manage. 19(Suppl. 1), S21-S25 (2000).
76. Carter GT. Galer BS. Advances in the management of neuropathic pain. Phys. Med. Rehabil. Clin. N. Am. 12(2), 447-459 (2001).
77. Attal N. Pharmacoiogic treatment of neuropathic pain. Acta Neurol. Belg. 101(1), 53-64 (2001).
78. MacPherson RD: New directions in pain management. Drugs Today (Barc) 38(2), 135-145 (2002).
79. Mattia C, Pholetti F, Coluzzi F, Boanelli A. New antidepressants in the treatment of neuropathic pain. A review. Minerva Anestesiol. 68(3), 105-114 (2002).
80. Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int. Rev. Neurobiol. 50, 393-413 (2002).
81. Backonja MM. Use of anticonvulsants for treatment of neuropathic pain. Neurology 59(Suppl. 2), S14-S17 (2002).
82. Sawynok J. Topical and peripherally acting analgesics. Pharmacol. Rev. 55 (1), 1-20 (2003).
83. Dworkin RH, Backonja M, Rowbotham MC et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch. Neurol. 60, 1524-1534 (2003).
84. Sah DW, Ossipo MH, Porreca F. Neurotrophic factors as novel therapeutics for neuropathic pain. Nat. Rev. Drug Discov. 2(6), 460-472 (2003).
85. Gardell LR, Wang R, Ehrenfels C et al. Multiple actions of systemic artemin in experimental neuropathy. Nat. Med. 9, 1383-1389 (2003).
86. Carrazana E, Mikoshiba I. Rationale and evidence for the use of oxcarbazepine in neuropathic pain. J. Pain Symptom Manag. 25. S31-S35 (2003).
87. Slonimski M, Abram SE, Zuniga RE. Intrathecal baclofen in pain management. Reg. Anesth. Pain Med. 29(3), 269-276 (2004).
88. Davies PS, Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 64(9), 937-947 (2004).
89. Nicholson BD. Evaluation and treatment of central pain syndromes. Neurology 62 (5 Suppl. 2), S30-S36 (2004).
90. Plaghki L, Adriaensen H, Morlion B, Lossignol D, Devulder J. Systematic overview of the pharmacological management of postherpetic neuralgia. An evaluation of the clinical value of critically selected drug treatments based on efficacy and safety outcomes from randomized controlled studies. Dermatology 208(3), 206-216 (2004).
91. Argoff CE, Katz N, Backonja M. Treatment of postherpetic neuralgia: a review of therapeutic options. J. Pain Symptom Manag. 28(4), 396-411 (2004).
92. Johnson RW, Whitton TL. Management of herpes zoster (shingles) and postherpetic neuralgia. Expert Opin. Pharmacother. 5(3), 551-559 (2004).
93. Dib JG. Focus on topiramate in neuropathic pain. Curr. Med. Res. Opin. 20(12), 1857-1861 (2004).
94. Valenzano KJ, Sun Q. Current perspectives on the therapeutic utility of VR1 antagonists. Curr. Med. Chem. 11(24), 3185-3202 (2004).
95. Maizels M, McCarberg B. Antidepressants and antiepileptic drugs for chronic non-cancer pain. Am. Fam. Physician 71(3), 483-490 (2005).
96. Irving GA. Contemporary assessment and management of neuropathic pain. Neurology 64(Suppl. 3), S21-S27 (2005).
97. Chong MS, Libretto SE. The rationale and use of topiramate for treating neuropathic pain. Clin. J. Pain 19 (1), 59-68 (2003).
98. Mattia C, Coluzzi F. Antidepressants in chronic neuropathic pain. Mini Rev. Med. Chem. 3(7), 773-784 (2003).
99. Peuckmann V, Strumpf M, Zenz M, Bruera E. Novel potential uses of thalidomide in the management of pain? A review of the literature. Schmerz 17(3), 204-210 (2003).
100. Argoff CE. A focused review on the use of botulinum toxins for neuropathic pain. Clin. J. Pain. 18 (6 Suppl.), S177-S181 (2002).
101. Wilson SP, Yeomans DC. Virally mediated delivery of enkephalin and other neuropeptide transgenes in experimental pain models. Ann. NY Acad. Sci. 971, 515-521 (2002).
102. Ribeiro, JA, Sebastiao AM, de Mendonca A. Adenosine receptors in the nervous system: pathophysiological implications. Prog. Neurobiol. 68(6), 377-392 (2002).
103. Chizh BA, Illes P. P2X receptors and nociception. Pharmacol. Rev. 53(4), 553-568 (2001).
104. Planells-Cases R, Perez-Paya E, Messeguer A, Carreno C, Ferrer-Montiel A. Small molecules targeting the NMDA receptor complex as drugs for neuropathic pain. Mini Rev. Med. Chem. 3(7), 749-756 (2003).
105. Prorok M, Castellino FJ. Structure-function relationships of the NMDA receptor antagonist conantokin peptides. Curr. Drug Tarpts 2(3), 313-322 (2001).
106. Szekely JI, Torok K, Mate G. The role of Ionotropic glutamate receptors in nociception with special regard to the AMPA binding sites. Curr. Pharm. Des. 8(10), 887-912 (2002).
107. Parsons CG. NMDA receptors as targets for drug action in neuropathic pain. Eur. J. Pharmacol. 429(1-3), 71-78 (2001).
108. Morales-Alcelay S, Rubio L, Martinez A. AMPA glutamate receptors and neuropathic pain. Mini Rev. Med. Chem. 3(7), 757-763 (2003).
109. Snutch TP, Sutton KG, Zamponi GW. Voltage-dependent calcium channels - beyond dihydropyridine antagonists. Curr. Opin. Pharmacol. 1(1), 11-16 (2001).
110. Jain KK. An evaluation of intrathecal ziconotide for the treatment of chronic pain. Expert Opin. Investig. Drugs 9(10), 2403-2410
111. Cox B. Calcium channel blockers and pain therapy. Curr. Rev. Pain 4(6), 488-498 (2000).
112. Winquist RJ, Pan JQ, Gribkoff VK. Use-dependent blockade of Cav2.2 voltage-gated calcium channels for neuropathic pain. Biochem. Pharmacol. 70(4), 489-499 (2005).
113. Strichartz GR, Zhou Z, Sinnott C, Khodorova A. Therapeutic concentrations of local anaesthetics unveil the potential role of sodium channels in neuropathic pain. Novartis Found. Symp. 241, 189-201 (2002).
114. Wood JN, Baker M. Voltage-gated sodium channels. Curr. Opin. Pharmacol. 1(1), 17-21 (2001).
115. Lai J, Porreca F, Hunter JC, Gold MS. Voltage-gated sodium channels and hyperalgesia. Annu. Rev. Pharmacol. Taxicol. 44, 371-397 (2004).
116. Blackburn-Munro G, Dalby-Brown W, Mirza NR, Mikkelsen JD, Blackburn-Munro RE. Retigabine: chemical synthesis to clinical application. CNS Drug Rev. 11(1), 1-20 (2005).
117. Goya P, Jagerovic N, Hernandez-Folgado L, Martin MI. Cannabiroids and neuropathic pain. Mini Rev. Med. Chem. 3(7), 765-772 (2003).
118. Malan TP Jr, Ibrahim MM, Lai J, Vanderah TW, Makriyannis A, Porreca F. CB2 cannabinoid receptor agonists: pain relief without psychoactive effects. Curr. Opin. Pharmacol. 3(1), 62-67 (2003).
119. Pertwee RG. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin. Invesug. Drugs 9(7), 1553-1571 (2000).
120. Pertwee RG. Cannabinoid receptors and pain. Prog. Neurobiol. 63(5), 569-611 (2001).
121. Szallasi A, Blumberg PM. Vanilloid receptors: new insights enhance potential as a therapeutic target. Pain 68(2-3), 195-208 (1996).
122. Lopez-Rodriguez KC, Viso A, Ortega-Gutierrez S. VR1 receptor modulators as potential drugs for neuropathic pain. Mini Rev. Med. Chem. 3(7), 729-748 (2003).
123. Szallasi A. Vanilloid receptor ligands: hopes and realities for the future. Drugy Aging 18(8), 561-573 (2001).
124. Desmeules JA. The tramadol option. Eur. J. Pain 4 (Suppl. A), 15-21 (2000).
125. Moran TD, Abdulla FA, Smith PA. Cellular neurophysiological actions of nociceptin/orphanin FQ. Peptides 21(7), 969-976 (2000).